From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Post Pfizer – what is Novacyt worth? Far from zero but it’s a slam dunk sell.

By Tom Winnifrith | Tuesday 10 November 2020

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Some of us were always of the view that our leaders were somewhat overreacting to a disease where the average casualty lived longer than UK life expectancy and where the survival rate is 99.97%. But yesterday, Pfizer announced it has a vaccine which will protect 90% of those injected which would mean that your chances of perishing from Covid will pretty soon be less than that of being mown down by a bus carrying a West Ham team that has just won the FA Cup. So where does that leave Covid testing play Novacyt (NCYT)?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Which PR genius wrote this?



H&T Group – now again a Buy

Time left: 11:44:39